Want to see CH:YPSN full AI Analyst Report?
YPSN Stock Chart & Stats
CHF400.40
CHF9.40(2.46%)
At close: 4:00 PM EDT
CHF400.40
CHF9.40(2.46%)
Day’s Range― - ―
52-Week RangeCHF260.50 - CHF419.50
Previous CloseN/A
Volume9.81K
Average Volume (3M)15.30K
Market Cap
CHF4.61B
Enterprise ValueCHF3.97K
Total Cash (Recent Filing)CHF28.56M
Total Debt (Recent Filing)CHF260.77M
Price to Earnings (P/E)21.3
Beta0.74
Next Earnings
Nov 11, 2026EPS Estimate
5.04Next Dividend Ex-DateN/A
Dividend Yield1.26%
Share Statistics
EPS (TTM)16.31
Shares Outstanding13,149,739
10 Day Avg. Volume19,839
30 Day Avg. Volume15,298
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)5.02
Price to Sales (P/S)5.14
P/FCF Ratio-229.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF442.33Price Target Upside10.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)12.77
Revenue Forecast (FY)CHF710.56M
Bulls Say, Bears Say
Bulls Say
Core Growth And MarginsThe core Delivery Systems business is expanding rapidly while already producing a high EBIT margin. Combining strong growth with solid profitability indicates improving operating scale and supports continued investment in products, capacity, and customer programs over the next several quarters.
Project Pipeline And Customer DiversificationRecord deal wins and a large, diversified pipeline provide multiple avenues for future commercialization rather than relying on one project or customer. The reported hit rate and broad client base strengthen visibility into medium-term growth and reduce concentration risk.
Product Innovation And IP DurabilityNew recyclable injection platforms address customer ecodesign priorities while extending Ypsomed’s intellectual-property protection for many years. This can reinforce differentiation, support new pharmaceutical programs, and preserve the company’s relevance as drug-delivery requirements evolve.
Bears Say
Persistent Negative Free Cash FlowAlthough operating cash generation improved materially, recurring negative free cash flow shows that investment and working-capital demands continue to absorb cash. This reduces internally funded financial flexibility and makes execution of the expansion plan more dependent on disciplined capital allocation.
Contract Manufacturing Phase-outThe planned phase-out removes a meaningful portion of reported revenue in the near term and creates a lower starting base for comparisons. Management expects only a low-single-digit-million EBIT effect, but the transition still requires replacement growth from higher-priority programs.
Ramp-up And Stranded Project CostsLarge footprint projects can temporarily leave capacity underutilized and add transition costs before full production efficiency is reached. These pressures may weigh on margins during the next phase of expansion, even if the investments ultimately support greater manufacturing capacity.
YPSN FAQ
What was Ypsomed Holding AG’s price range in the past 12 months?
Ypsomed Holding AG lowest stock price was CHF260.50 and its highest was CHF419.50 in the past 12 months.
What is Ypsomed Holding AG’s market cap?
Ypsomed Holding AG’s market cap is CHF4.61B.
When is Ypsomed Holding AG’s upcoming earnings report date?
Ypsomed Holding AG’s upcoming earnings report date is Nov 11, 2026 which is in 54 days.
How were Ypsomed Holding AG’s earnings last quarter?
Ypsomed Holding AG released its earnings results on May 20, 2026. The company reported CHF6.11 earnings per share for the quarter, beating the consensus estimate of CHF6 by CHF0.11.
Is Ypsomed Holding AG overvalued?
According to Wall Street analysts Ypsomed Holding AG’s price is currently Undervalued.
Does Ypsomed Holding AG pay dividends?
Ypsomed Holding AG pays a Annually dividend of CHF4.4 which represents an annual dividend yield of 1.26%. See more information on Ypsomed Holding AG dividends here
What is Ypsomed Holding AG’s EPS estimate?
Ypsomed Holding AG’s EPS estimate is 5.04.
How many shares outstanding does Ypsomed Holding AG have?
Ypsomed Holding AG has 13,149,739 shares outstanding.
What happened to Ypsomed Holding AG’s price movement after its last earnings report?
Ypsomed Holding AG reported an EPS of CHF6.11 in its last earnings report, beating expectations of CHF6. Following the earnings report the stock price went up 9.33%.
Which hedge fund is a major shareholder of Ypsomed Holding AG?
Currently, no hedge funds are holding shares in CH:YPSN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ypsomed Holding AG
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for safe and simple self-medication companies. The company operates through three segments: Ypsomed Delivery Systems, Ypsomed Diabetes Care, and Others. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto-injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories, and other day-to-day items for diabetics. This segment offers its products under the mylife brand name. The company offers precision turned parts; and contract manufacturing and other services. It markets its products through pharmaceutical partners, as well as through its own distribution network and independent distributors. It operates in Switzerland, Europe, North America, and internationally. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.
YPSN Stock 12 Month Forecast
Average Price Target
CHF442.33
▲(10.47% Upside)
Technical Analysis
Lonza Group Ltd
―
DKSH Holding AG
―
medmix AG
―
Roche Holding Ltd
―
Lepu Medical Technology (Beijing) Co., Ltd. Sponsored Global Depositary Receipt Repr Sh -A- Reg S
―



